Literature DB >> 8087143

P53 accumulation in precursor lesions and early stages of bladder cancer.

B J Schmitz-Dräger1, C R van Roeyen, M O Grimm, C D Gerharz, K Decken, W A Schulz, H Bültel, D Makri, T Ebert, R Ackermann.   

Abstract

Recent investigations have demonstrated alterations of the p53 tumor-suppressor gene in a considerable number of transitional-cell carcinoma (TCC) specimens. Thus far, these investigations have been restricted to either papillary TCC or invasive bladder cancer. To obtain further information on a possible involvement of p53 in bladder cancer development or tumor progression, investigations of precursor lesions and early stages of this disease are required. Immunohistochemical examination of 6 dysplasias and 24 carcinomas in situ (TIS) showed p53 accumulation, which is suggestive of p53 inactivation, in 2 (33%) and 9 (38%) of these specimens, respectively. This ratio was similar in 9 T1 lesions (33%) and in 14 cases of muscle-infiltrative disease (35%). In papillary tumors, p53 accumulation was observed exclusively in 3/10 moderately differentiated or high-grade lesions but not in 1 Ta G1 tumor. The expression of p53 accumulation was a consistent finding. The examination of tumor recurrences yielded either the presence or the absence of p53 overexpression in the primary and recurrent tumors of 7/8 patients. Similarly, in multifocal TCC, p53 accumulation was also either present or absent in 10/11 cases examined. These results suggest the existence of at least two different subgroups of TCC, with p53 accumulation being present in one of these groups. The observation of p53 accumulation in dysplasia and in TIS is a prerequisite for a possible involvement of p53 in bladder cancer carcinogenesis, although it does not prove this assumption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087143     DOI: 10.1007/bf00184241

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.

Authors:  J Bargonetti; P N Friedman; S E Kern; B Vogelstein; C Prives
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

3.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 4.  Urothelial dysplasia.

Authors:  W M Murphy; M S Soloway
Journal:  J Urol       Date:  1982-05       Impact factor: 7.450

5.  Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.

Authors:  A F Olumi; Y C Tsai; P W Nichols; D G Skinner; D R Cain; L I Bender; P A Jones
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.

Authors:  Y C Tsai; P W Nichols; A L Hiti; Z Williams; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

8.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

9.  Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.

Authors:  P K Lipponen
Journal:  Int J Cancer       Date:  1993-02-01       Impact factor: 7.396

10.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

View more
  7 in total

Review 1.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  Accumulation of p53 protein in inverted transitional cell papilloma of the urinary bladder.

Authors:  K W Chan; K Y Lam; G Srivastava
Journal:  Clin Mol Pathol       Date:  1996-02

3.  Inverted papilloma of the urinary bladder: a case evaluated for malignant potential.

Authors:  S Urakami; M Igawa; H Shirakawa; H Shiina; T Ishibe
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines.

Authors:  M O Grimm; B Jürgens; W A Schulz; K Decken; D Makri; B J Schmitz-Dräger
Journal:  Urol Res       Date:  1995

5.  Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.

Authors:  M A Kuczyk; J Serth; C Hervatin; H Arndt; L Derendorf; W F Thon; U Jonas
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

6.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

Authors:  S Clasen; W A Schulz; C D Gerharz; M O Grimm; F Christoph; B J Schmitz-Dräger
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

Review 7.  Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example.

Authors:  Peggy Sekula; Julia B Pressler; Willi Sauerbrei; Peter J Goebell; Bernd J Schmitz-Dräger
Journal:  BMJ Open       Date:  2016-08-16       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.